Price (delayed)
$10.17
Market cap
$12.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
$165.14M
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults
There are no recent dividends present for ACOR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.